Eli Lilly and Company (NYSE: LLY) announced that Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO).

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

8/6/2019 11:36:00 AM

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.

Updated Disease Classification System Adopted by the World Health Organization

8/1/2019 7:19:00 AM

On 25 May 2019, the World Health Assembly officially adopted the eleventh revision of the International Classification of Diseases (ICD-11). The ICD-11 will come into effect on 1 January 2022.

FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)

8/1/2019 7:09:00 AM

Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab)i , for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. Please see full indications and Boxed Warning for HADLIMA™, below.

More News

Subscribe to News feed

The mechanistic model(s) of psoriasis: Autoimmune and/or inflammatory?

Hot topics and challenging cases in psoriasis: A focus on pustular, biosimilars, pediatrics and treating in under-served areas

Video Lectures by World Experts

Watch Now

Our Work

Psoriasis Leadership

Advancing Research

Review our Publications

Growing Psoriasis Expertise

Education & Resources

CME Programs

Expert Perspectives

Put the latest psoriasis Research into context

Complex Cases

Upcoming IPC Events

September 18

October 9

November 8

Psoriasis News

Advancing Knowledge. Enhancing Care.